Latvja - Latvjan - Zāļu valsts aģentūra

sanofi pasteur, france - difterijas, stingumkrampju, garā klepus, poliomielīta (inaktivēta) un b tipa haemophilus influenzae konjugēta vakcīna (adsorbēta) - pulveris un suspensija injekciju suspensijas pagatavošanai pilnšļircē

Latvja - Latvjan - Zāļu valsts aģentūra

sanofi pasteur, france - difterijas, stingumkrampju, acelulāra garā klepus un poliomielīta (inaktivēta) vakcīna (adsorbēta) - suspensija injekcijām pilnšļircē

Latvja - Latvjan - Zāļu valsts aģentūra

sanofi pasteur, france - trakumsērgas vīruss (inaktivēts) - pulveris un šķīdinātājs injekciju suspensijas pagatavošanai

Latvja - Latvjan - Zāļu valsts aģentūra

sanofi pasteur, france - a hepatīta vakcīna (inaktivēta, adsorbēta) - suspensija injekcijām pilnšļircē - 160 v

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripas, cilvēka - gripas vakcīna, inaktivēta, šķelta viriona vai virsmas antigēna - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra būtu jāizmanto saskaņā ar oficiālās rekomendācijas.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - gripas, cilvēka - vakcīnas - profilakse gripas veci cilvēki (65 gadus veci un vecāki). fluad tetra būtu jāizmanto saskaņā ar oficiālās rekomendācijas.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunoloģiskie līdzekļi suidae - cūkas (nobarošanas) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Latvja - Latvjan - Pārtikas un veterinārais dienests, Zemkopības ministrija

boehringer ingelheim animal health france scs , francija - canine adenovirus type 2, strain dk13, canine distemper virus, strain ba5, canine parvovirus type 2, strain cag2, canine parainfluenza virus type 2, strain cgf 2004/75, leptospira interrogans, serogroup canicola, serovar canicola, strain 16070, inactivated, leptospira interrogans, serogroup icterohaemorrhagiae, serovar icterohaemorrhagiae, strain 16069, inactivated, leptospira interrogans, serogroup grippotyphosa, serovar grippotyphosa, strain grippo mal 1540, inactivated - liofilizāts un suspensija suspensijas injekcijām pagatavošanai - suņi

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vakcīnas - active immunisation against h5 subtype of influenza a virus.

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

ceva santé animale - inaktivēta coxiella burnetii vakcīna, deviņu mile celms - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.